OLIG3

Summary

OLIG3 (oligodendrocyte transcription factor 3, HGNC:18003) is a protein-coding gene on chromosome 6q23.3, encoding Oligodendrocyte transcription factor 3 (Q7RTU3). May determine the distinct specification program of class A neurons in the dorsal part of the spinal cord and suppress specification of class B neurons.

Enables sequence-specific double-stranded DNA binding activity. Predicted to be involved in axon development; positive regulation of transcription by RNA polymerase II; and sensory organ development. Predicted to act upstream of or within negative regulation of transcription by RNA polymerase II; spinal cord motor neuron cell fate specification; and spinal cord motor neuron migration. Predicted to be located in chromatin. Predicted to be active in nucleus.

Source: NCBI Gene 167826 — RefSeq curated summary.

At a glance

• GWAS associations: 21
• Clinical variants (ClinVar): 44 total
• MANE Select transcript: NM_175747

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:18003
Approved symbol	OLIG3
Name	oligodendrocyte transcription factor 3
Location	6q23.3
Locus type	gene with protein product
Status	Approved
Aliases	Bhlhb7, bHLHe20
Ensembl gene	ENSG00000177468
Ensembl biotype	protein_coding
OMIM	609323
Entrez	167826

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 protein_coding

ENST00000367734

RefSeq mRNA: 1 — MANE Select: NM_175747 NM_175747

CCDS: CCDS5186

Canonical transcript exons

ENST00000367734 — 1 exons

Exon	Start	End
ENSE00001445513	137492199	137494394

Expression profiles

Bgee: expression breadth broad, 15 present calls, max score 53.55.

FANTOM5 (CAGE): breadth broad, TPM avg 2.3116 / max 169.6180, expressed in 191 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
75823	2.3116	191

Top tissues by expression

237 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
islet of Langerhans	UBERON:0000006	53.55	gold quality
cerebellar vermis	UBERON:0004720	49.48	gold quality
thymus	UBERON:0002370	44.46	gold quality
lower lobe of lung	UBERON:0008949	43.40	silver quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	43.37	gold quality
amniotic fluid	UBERON:0000173	42.81	gold quality
secondary oocyte	CL:0000655	42.57	gold quality
quadriceps femoris	UBERON:0001377	42.30	gold quality
vastus lateralis	UBERON:0001379	41.41	gold quality
superficial temporal artery	UBERON:0001614	41.33	gold quality
palpebral conjunctiva	UBERON:0001812	41.10	gold quality
mucosa of paranasal sinus	UBERON:0005030	40.98	gold quality
ganglionic eminence	UBERON:0004023	40.61	gold quality
jejunal mucosa	UBERON:0000399	40.59	gold quality
biceps brachii	UBERON:0001507	40.57	gold quality
medulla oblongata	UBERON:0001896	40.52	gold quality
epithelium of nasopharynx	UBERON:0001951	40.45	gold quality
myocardium	UBERON:0002349	40.45	gold quality
gingival epithelium	UBERON:0001949	40.43	gold quality
duodenum	UBERON:0002114	40.34	gold quality
germinal epithelium of ovary	UBERON:0001304	40.33	gold quality
esophagus squamous epithelium	UBERON:0006920	40.29	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	40.27	gold quality
jejunum	UBERON:0002115	40.18	gold quality
cartilage tissue	UBERON:0002418	40.06	gold quality
oviduct epithelium	UBERON:0004804	40.03	gold quality
mammary duct	UBERON:0001765	39.98	gold quality
mucosa of sigmoid colon	UBERON:0004993	39.95	gold quality
deltoid	UBERON:0001476	39.83	gold quality
saphenous vein	UBERON:0007318	39.83	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	1.15

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

1 targets.

Target	Regulation
NEUROG1	Unknown

JASPAR motifs

Motif	Name	Family
MA0827.1	OLIG3	Tal-related

JASPAR matrix evidence (PMIDs): PMID:20959288

miRNA regulators (miRDB)

77 targeting OLIG3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-574-5P	100.00	66.01	989
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-507	99.97	70.11	1915
HSA-MIR-34C-5P	99.97	70.45	1577
HSA-MIR-449B-5P	99.97	70.26	1580
HSA-MIR-557	99.96	70.01	1640
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-6508-5P	99.92	70.67	2465
HSA-MIR-3119	99.92	71.34	2390
HSA-MIR-7-1-3P	99.91	71.53	4384
HSA-MIR-7-2-3P	99.91	71.40	4394
HSA-MIR-3529-3P	99.90	73.55	3045
HSA-MIR-9902	99.89	69.15	2250
HSA-MIR-579-3P	99.86	71.66	3628
HSA-MIR-8067	99.86	69.59	2260
HSA-MIR-664B-3P	99.84	71.65	3590
HSA-MIR-6756-5P	99.82	67.97	2466
HSA-MIR-7110-5P	99.80	67.84	1712
HSA-MIR-6842-5P	99.80	67.54	1587
HSA-MIR-6817-3P	99.79	68.35	2126

Literature-anchored findings (GeneRIF, showing 2)

• SNP within the OLIG3/TNFAIP3 locus (rs6920220) was associated with being less likely to maintain MTX monotherapy (PMID:20921970)
• Two identified variants revealed novel candidate genes for hip and knee osteoarthritis. OLIG3 and FIP1L1 have specific roles in transcription and may effect expression of other genes. Identified variants in these genes may thus have a role in the regulatory events leading to osteoarthritis. (PMID:30157244)

Cross-species orthologs

8 orthologs

Organism	Symbol	Gene ID
danio_rerio	olig3	ENSDARG00000074253
mus_musculus	Olig3	ENSMUSG00000045591
rattus_norvegicus	Olig3	ENSRNOG00000064127
drosophila_melanogaster	amos	FBGN0003270
drosophila_melanogaster	ato	FBGN0010433
drosophila_melanogaster	tap	FBGN0015550
caenorhabditis_elegans		WBGENE00003018
caenorhabditis_elegans		WBGENE00003595

Paralogs (15): NEUROG3 (ENSG00000122859), NEUROD4 (ENSG00000123307), BHLHE23 (ENSG00000125533), NEUROD1 (ENSG00000162992), NEUROD6 (ENSG00000164600), ATOH8 (ENSG00000168874), NEUROD2 (ENSG00000171532), ATOH1 (ENSG00000172238), NEUROG2 (ENSG00000178403), ATOH7 (ENSG00000179774), BHLHA15 (ENSG00000180535), BHLHE22 (ENSG00000180828), NEUROG1 (ENSG00000181965), OLIG1 (ENSG00000184221), OLIG2 (ENSG00000205927)

Protein

Protein identifiers

Oligodendrocyte transcription factor 3 — Q7RTU3 (reviewed: Q7RTU3)

Alternative names: Class B basic helix-loop-helix protein 7, Class E basic helix-loop-helix protein 20

All UniProt accessions (1): Q7RTU3

UniProt curated annotations — full annotation on UniProt →

Function. May determine the distinct specification program of class A neurons in the dorsal part of the spinal cord and suppress specification of class B neurons.

Subcellular location. Nucleus.

RefSeq proteins (1): NP_786923* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR011598	bHLH_dom	Domain
IPR032659	Olig3_bHLH	Domain
IPR036638	HLH_DNA-bd_sf	Homologous_superfamily
IPR050359	bHLH_transcription_factors	Family

Pfam: PF00010

UniProt features (7 total): compositionally biased region 3, chain 1, domain 1, region of interest 1, coiled-coil region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q7RTU3-F1	63.67	0.26

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 140 (showing top): GOBP_SPINAL_CORD_DEVELOPMENT, CREL_01, BENPORATH_ES_WITH_H3K27ME3, GOBP_NEUROGENESIS, RACCACAR_AML_Q6, FOXO4_01, FOXO1_01, GOBP_CELL_DIFFERENTIATION_IN_SPINAL_CORD, GOBP_SPINAL_CORD_MOTOR_NEURON_DIFFERENTIATION, EVI1_05, GOBP_VENTRAL_SPINAL_CORD_DEVELOPMENT, GOBP_SPINAL_CORD_MOTOR_NEURON_CELL_FATE_SPECIFICATION, AML_Q6, GOBP_NEURON_FATE_SPECIFICATION, GOBP_CENTRAL_NERVOUS_SYSTEM_NEURON_DIFFERENTIATION

GO Biological Process (8): negative regulation of transcription by RNA polymerase II (GO:0000122), sensory organ development (GO:0007423), spinal cord motor neuron cell fate specification (GO:0021520), positive regulation of transcription by RNA polymerase II (GO:0045944), axon development (GO:0061564), spinal cord motor neuron migration (GO:0097476), regulation of gene expression (GO:0010468), spinal cord motor neuron differentiation (GO:0021522)

GO Molecular Function (6): DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), protein dimerization activity (GO:0046983), E-box binding (GO:0070888), sequence-specific double-stranded DNA binding (GO:1990837), DNA binding (GO:0003677), protein binding (GO:0005515)

GO Cellular Component (2): chromatin (GO:0000785), nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of transcription by RNA polymerase II	3
transcription by RNA polymerase II	2
negative regulation of DNA-templated transcription	1
animal organ development	1
spinal cord motor neuron differentiation	1
neuron fate specification	1
positive regulation of DNA-templated transcription	1
neuron projection development	1
motor neuron migration	1
gene expression	1
regulation of macromolecule biosynthetic process	1
cell differentiation in spinal cord	1
ventral spinal cord development	1
central nervous system neuron differentiation	1
chromatin	1
RNA polymerase II transcription regulatory region sequence-specific DNA binding	1
DNA-binding transcription factor activity	1
protein binding	1
RNA polymerase II cis-regulatory region sequence-specific DNA binding	1
double-stranded DNA binding	1
sequence-specific DNA binding	1
nucleic acid binding	1
binding	1
chromosome	1
cellular anatomical structure	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

866 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
OLIG3	TNFAIP3	P21580	801
OLIG3	AVPR2	P30518	668
OLIG3	PTPN22	Q9Y2R2	644
OLIG3	PIP4K2C	Q8TBX8	626
OLIG3	TRAF1	Q13077	606
OLIG3	DBX1	A6NMT0	571
OLIG3	PADI4	Q9UM07	568
OLIG3	GBX2	P52951	560
OLIG3	NKX2-2	O95096	553
OLIG3	TCF3	P15883	539
OLIG3	KIF5A	Q12840	536
OLIG3	IRF5	Q13568	532
OLIG3	TNFRSF14	Q92956	491
OLIG3	DBX2	Q6ZNG2	484
OLIG3	PAX6	P26367	479

IntAct

110 interactions, top by confidence:

A	B	Type	Score
OLIG3	TRAF1	psi-mi:“MI:0915”(physical association)	0.720
MDFI	OLIG3	psi-mi:“MI:0915”(physical association)	0.720
OLIG3	MDFI	psi-mi:“MI:0915”(physical association)	0.720
TRAF1	OLIG3	psi-mi:“MI:0915”(physical association)	0.720
ARID5A	OLIG3	psi-mi:“MI:0915”(physical association)	0.600
TLE5	OLIG3	psi-mi:“MI:0915”(physical association)	0.560
BYSL	OLIG3	psi-mi:“MI:0915”(physical association)	0.560
OLIG3	BYSL	psi-mi:“MI:0915”(physical association)	0.560
KRTAP10-8	OLIG3	psi-mi:“MI:0915”(physical association)	0.560
CADPS	OLIG3	psi-mi:“MI:0915”(physical association)	0.560
MFAP1	OLIG3	psi-mi:“MI:0915”(physical association)	0.560
KRTAP1-1	OLIG3	psi-mi:“MI:0915”(physical association)	0.560
CYSRT1	OLIG3	psi-mi:“MI:0915”(physical association)	0.560
OLIG3	CARD10	psi-mi:“MI:0915”(physical association)	0.560
KRTAP6-3	OLIG3	psi-mi:“MI:0915”(physical association)	0.560
PROP1	OLIG3	psi-mi:“MI:0915”(physical association)	0.560
OLIG3	WWOX	psi-mi:“MI:0915”(physical association)	0.560
OLIG3	PLAGL2	psi-mi:“MI:0915”(physical association)	0.560
KRTAP19-5	OLIG3	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (35): OLIG3 (Two-hybrid), OLIG3 (Two-hybrid), OLIG3 (Two-hybrid), OLIG3 (Two-hybrid), TRAF1 (Two-hybrid), OLIG3 (Two-hybrid), OLIG3 (Two-hybrid), OLIG3 (Two-hybrid), OLIG3 (Two-hybrid), OLIG3 (Two-hybrid), OLIG3 (Two-hybrid), OLIG3 (Two-hybrid), OLIG3 (Two-hybrid), OLIG3 (Two-hybrid), OLIG3 (Two-hybrid)

ESM2 similar proteins: A3KMR8, A7Z017, B3DM47, B4R090, D3ZNT6, O35317, O35984, O42290, O57342, O75030, O75444, P10083, P23091, P25932, P40424, P40425, P40426, P41778, P54841, P54842, P54843, P54844, P56224, P57102, P61295, P61296, P79745, P79746, Q05192, Q0V9K1, Q27350, Q2PFS4, Q32NP8, Q4U1U2, Q504L8, Q61039, Q6DE84, Q6PFG8, Q789F3, Q7RTU3

Diamond homologs: A8E5T6, B6VQA1, O09029, O09105, O13125, O13126, O16867, O35437, O42202, O42606, O43680, O45489, O57598, O88940, O96004, O96642, P10627, P13903, P46581, P48985, P48986, P48987, P57100, P57101, P57102, P59101, P61295, P61296, P70447, P70562, P70595, P70660, P70661, P79765, P79766, P79782, P79920, P97832, Q08DI0, Q0V9X5

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 30 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Keratinization	12	31.8×	2e-14

Disease & clinical

Clinical variants and AI predictions

ClinVar

44 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	42
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

92 predictions. Top by Δscore:

Variant	Effect	Δscore
6:137493354:A:AC	donor_gain	0.9300
6:137493355:C:CC	donor_gain	0.9300
6:137492862:C:CC	acceptor_gain	0.8100
6:137492861:ACTGT:A	acceptor_gain	0.7600
6:137493365:T:TA	donor_gain	0.7300
6:137493319:C:CA	donor_gain	0.7200
6:137492862:CTGT:C	acceptor_gain	0.7100
6:137492863:T:A	acceptor_gain	0.6700
6:137493348:CTGCT:C	donor_loss	0.6300
6:137493350:GCTCA:G	donor_loss	0.6300
6:137493351:CTCAC:C	donor_loss	0.6300
6:137493352:TCACT:T	donor_loss	0.6300
6:137493353:CA:C	donor_loss	0.6300
6:137493354:ACTT:A	donor_loss	0.6300
6:137493355:C:CA	donor_loss	0.6300
6:137492900:T:TG	acceptor_gain	0.6200
6:137493325:T:TA	donor_gain	0.5900
6:137492860:AACTG:A	acceptor_gain	0.5800
6:137493347:GCTGC:G	donor_loss	0.5100
6:137492859:AAACT:A	acceptor_gain	0.4800
6:137493355:CT:C	donor_gain	0.4800
6:137492861:A:AC	acceptor_gain	0.4600
6:137493349:TGCTC:T	donor_loss	0.4500
6:137493355:CTTGA:C	donor_gain	0.4400
6:137493143:TAC:T	donor_gain	0.4200
6:137493322:T:TA	donor_gain	0.4200
6:137492858:AAAAC:A	acceptor_gain	0.3900
6:137493142:C:CT	donor_gain	0.3700
6:137493143:T:TT	donor_gain	0.3700
6:137493355:CTT:C	donor_gain	0.3700

AlphaMissense

1766 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
6:137493439:G:C	C244W	1.000
6:137493440:C:T	C244Y	1.000
6:137493441:A:G	C244R	1.000
6:137493450:A:G	C241R	1.000
6:137493456:A:G	C239R	1.000
6:137493731:A:G	L147P	1.000
6:137493740:A:C	M144R	1.000
6:137493749:A:G	L141P	1.000
6:137493752:G:A	S140F	1.000
6:137493753:A:G	S140P	1.000
6:137493761:A:G	L137P	1.000
6:137493761:A:T	L137H	1.000
6:137493762:G:A	L137F	1.000
6:137493763:C:A	M136I	1.000
6:137493763:C:G	M136I	1.000
6:137493763:C:T	M136I	1.000
6:137493767:A:G	L135P	1.000
6:137493770:A:C	I134S	1.000
6:137493770:A:G	I134T	1.000
6:137493770:A:T	I134N	1.000
6:137493771:T:A	I134F	1.000
6:137493773:T:C	Y133C	1.000
6:137493774:A:C	Y133D	1.000
6:137493775:G:C	N132K	1.000
6:137493775:G:T	N132K	1.000
6:137493776:T:A	N132I	1.000
6:137493779:C:A	R131I	1.000
6:137493782:G:A	A130V	1.000
6:137493782:G:T	A130D	1.000
6:137493783:C:G	A130P	1.000

dbSNP variants (sampled 300 via entrez): RS1001376852 (6:137492319 AC>A), RS1001769031 (6:137492033 C>T), RS1002205706 (6:137494470 C>G,T), RS1002367157 (6:137493293 G>A,C,T), RS1002408535 (6:137493116 C>G,T), RS1002629315 (6:137495315 A>G), RS1002765118 (6:137495465 G>C,T), RS1002787055 (6:137493492 G>T), RS1004568851 (6:137495207 AT>A), RS1004919917 (6:137494913 G>A), RS1005109891 (6:137493998 C>G,T), RS1005568345 (6:137496300 T>C), RS1006079764 (6:137495295 G>A), RS1006243038 (6:137496115 T>C), RS1006625273 (6:137492725 C>A)

Disease associations

OMIM: gene MIM:609323 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

21 associations (top):

Study	Trait	p-value
GCST000122_1	Rheumatoid arthritis	1.000000e-09
GCST000122_2	Rheumatoid arthritis	1.000000e-07
GCST000232_6	Rheumatoid arthritis	2.000000e-09
GCST000677_4	Rheumatoid arthritis	2.000000e-06
GCST001198_63	Multiple sclerosis	1.000000e-08
GCST001859_59	Thiazide-induced adverse metabolic effects in hypertensive patients	9.000000e-06
GCST002955_1	Forced expiratory volume in 1 second (occupational environmental exposures interaction)	4.000000e-07
GCST003075_10	Cognitive decline rate in late mild cognitive impairment	2.000000e-10
GCST003075_127	Cognitive decline rate in late mild cognitive impairment	2.000000e-10
GCST003129_28	Primary biliary cholangitis	1.000000e-10
GCST003995_32	Tonsillectomy	3.000000e-08
GCST005014_31	Tonsillectomy	3.000000e-08
GCST005523_24	Celiac disease	5.000000e-30
GCST005523_42	Celiac disease	2.000000e-07
GCST006048_2	Rheumatoid arthritis (ACPA-positive)	2.000000e-18
GCST007062_3	Hodgkin’s lymphoma	3.000000e-08
GCST007400_14	Systemic lupus erythematosus	2.000000e-13
GCST007798_79	Asthma	2.000000e-10
GCST007800_65	Asthma (childhood onset)	3.000000e-13
GCST008644_12	Celiac disease and Rheumatoid arthritis	3.000000e-27
GCST009597_316	Multiple sclerosis	5.000000e-25

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:0004530	triglyceride measurement
EFO:0004314	forced expiratory volume
EFO:0006993	response to mineral dust exposure
EFO:0007710	cognitive decline measurement
EFO:0007924	tonsillectomy risk measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

38 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	decreases expression, affects cotreatment, increases expression, affects expression	7
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	decreases expression, affects cotreatment, increases expression	3
Benzo(a)pyrene	affects methylation, decreases expression, decreases methylation, increases expression	3
Ethanol	affects cotreatment, increases expression, decreases expression	2
bisphenol A	decreases expression	1
N(4)-hydroxycytidine	increases expression	1
terbufos	increases methylation	1
trichostatin A	increases expression	1
arsenite	increases methylation	1
tetrabromobisphenol A	decreases expression	1
perfluorooctanoic acid	increases expression	1
S-(1,2-dichlorovinyl)cysteine	affects cotreatment, decreases expression, affects response to substance, increases expression	1
entinostat	affects cotreatment, increases expression	1
Chir 99021	affects cotreatment, increases expression	1
ramelteon	decreases expression	1
nilotinib	increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
Dabigatran	increases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Panobinostat	affects cotreatment, increases expression	1
Abacavir	increases expression	1
Cadmium	decreases expression, increases abundance	1
Caffeine	increases expression	1
Diethylhexyl Phthalate	decreases expression	1
Fonofos	increases methylation	1
Fluorouracil	decreases expression	1
Folic Acid	increases expression, affects cotreatment	1
Lipopolysaccharides	increases expression, affects cotreatment, decreases expression, affects response to substance	1
Parathion	increases methylation	1
Phenytoin	increases expression	1

Cellosaurus cell lines

3 cell lines: 3 embryonic stem cell

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_A4Z6	SEES3-1V human OLIG3, clone1	Embryonic stem cell	Male
CVCL_A4Z7	SEES3-1V human OLIG3, clone2	Embryonic stem cell	Male
CVCL_A4Z8	SEES3-1V human OLIG3, clone3	Embryonic stem cell	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.